Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).

被引：76
|
作者：
Nakamura, Atsushi
Inoue, Akira
Morita, Satoshi
Hosomi, Yukio
Kato, Terufumi
Fukuhara, Tatsuro
Gemma, Akihiko
Takahashi, Kazuhisa
Fujita, Yuka
Harada, Toshiyuki
Minato, Koichi
Takamura, Kei
Kobayashi, Kunihiko
Nukiwa, Toshihiro
机构：
[1] Sendai Kousei Hosp, Sendai, Miyagi, Japan
[2] Tohoku Univ, Dept Palliat Med, Sch Med, Sendai, Miyagi, Japan
[3] Kyoto Univ, Dept Biomed Stat & Bioinformat, Grad Sch Med, Kyoto, Japan
[4] Komagome Hosp, Dept Thorac Oncol & Resp Med, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[5] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan
[6] Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi, Japan
[7] Nippon Med Sch, Dept Pulm Med & Oncol, Tokyo, Japan
[8] Juntendo Univ, Dept Resp Med, Sch Med, Tokyo, Japan
[9] Natl Hosp Org Asahikawa Med Ctr, Dept Resp Med, Asahikawa, Hokkaido, Japan
[10] JCHO Hokkaido Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan
[11] Gunma Prefectural Canc Ctr, Div Resp Med, Ota, Japan
[12] Obihiro Kosei Gen Hosp, Dept Med 1, Obihiro, Hokkaido, Japan
[13] Saitama Med Univ Int Med Ctr, Dept Resp Med, Hidaka, Japan
[14] Tohoku Univ, Dept Resp Med, Sendai, Miyagi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9005
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Combination therapy with gefitinib and fulvestrant (G/F) for women with non-small cell lung cancer (NSCLC).
    Traynor, AM
    Schiller, JH
    Stabile, LP
    Kolesar, JM
    Belani, CP
    Hoang, T
    Dubey, S
    Eickhoff, J
    Marcotte, SM
    Siegfried, JM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 676S - 676S
  • [22] A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations.
    Choi, Moon Ki
    Hong, Jung Yong
    Chang, Won Jin
    Kim, Moonjin
    Kim, Sungmin
    Jung, Hyun Ae
    Lim, Sung Hee
    Lee, Ji Yun
    Do, Ingu
    Chol, Yoon-La
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Kounchil
    Ahn, Myung-Ju
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] Serum EGFR in patients with non-small cell lung cancer (NSCLC) treated with gefitinib
    Spreafico, A
    Gregorc, V
    Ludovini, V
    Pistola, L
    Amoroso, M
    Tofanetti, F
    Compagnoni, A
    Aondio, G
    Tonato, M
    Villa, E
    LUNG CANCER, 2005, 49 : S112 - S113
  • [24] Combination therapy with gefitinib and fulvestrant (G/F) for women with non-small cell lung cancer (NSCLC)
    Dubey, S
    Siegfried, J
    Stabile, L
    Kolesar, J
    Belani, C
    Hoang, T
    Eickhoff, J
    Marcotte, S
    Schiller, J
    Traynor, A
    LUNG CANCER, 2005, 49 : S87 - S88
  • [25] LONG-TERM SURVIVORS IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS: DATA FROM A RANDOMIZED PHASE III STUDY COMPARING GEFITINIB WITH CARBOPLATIN PLUS PACLITAXEL (NEJ002)
    Minegishi, Y.
    Kobayashi, K.
    Maemondo, M.
    Inoue, A.
    Sugawara, S.
    Oizumi, S.
    Hagiwara, K.
    Nukiwa, T.
    Morita, S.
    Gemma, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 412 - 412
  • [26] A FINAL RESULTS OF A PHASE II STUDY OF FIRST-LINE GEFITINIB FOR ELDERLY PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS; NEJ 003 STUDY
    Inoue, A.
    Minegishi, Y.
    Maemondo, M.
    Okinaga, S.
    Morikawa, N.
    Kobayashi, K.
    Harada, M.
    Hagiwara, K.
    Nukiwa, T.
    Gemma, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 141 - 142
  • [27] Phase II study of the efficacy of gefitinib in patients with non-small cell lung cancer with the EGFR mutations.
    Sunaga, N.
    Yanagitani, N.
    Kaira, K.
    Tomizawa, Y.
    Iijima, H.
    Otani, Y.
    Tanaka, S.
    Suga, T.
    Dobashi, K.
    Mori, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 409S - 409S
  • [28] RANDOMIZED PHASE II STUDY OF CONCURRENT GEFITINIB PLUS CHEMOTHERAPY VERSUS ALTERNATION OF GEFITINIB AND CHEMOTHERAPY IN PREVIOUSLY UNTREATED NON-SMALL CELL LUNG CANCER (NSCLC) WITH SENSITIVE EGFR MUTATIONS: NEJ005/TCOG0902
    Oizumi, S.
    Sakakibara-Konishi, J.
    Inoue, A.
    Kobayashi, K.
    Gemma, A.
    Yoshizawa, H.
    Isobe, H.
    Saijyo, Y.
    Ishii, Y.
    Morita, S.
    Hagiwara, K.
    Nukiwa, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 23 - 23
  • [29] A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
    J J Yang
    Q Zhou
    H H Yan
    X C Zhang
    H J Chen
    H Y Tu
    Z Wang
    C R Xu
    J Su
    B C Wang
    B Y Jiang
    X Y Bai
    W Z Zhong
    X N Yang
    Y L Wu
    British Journal of Cancer, 2017, 116 : 568 - 574
  • [30] A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
    Yang, J. J.
    Zhou, Q.
    Yan, H. H.
    Zhang, X. C.
    Chen, H. J.
    Tu, H. Y.
    Wang, Z.
    Xu, C. R.
    Su, J.
    Wang, B. C.
    Jiang, B. Y.
    Bai, X. Y.
    Zhong, W. Z.
    Yang, X. N.
    Wu, Y. L.
    BRITISH JOURNAL OF CANCER, 2017, 116 (05) : 568 - 574
12345